These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

144 related items for PubMed ID: 30843996

  • 1. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN, Tan PS, Simko S, Barreto CMN, Gutierres BS, Giglio AD, Lopes GL.
    Einstein (Sao Paulo); 2019 Mar 07; 17(2):eGS4414. PubMed ID: 30843996
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost Effectiveness of Systemic Treatment Intensification for Metastatic Hormone-sensitive Prostate Cancer: Is Triplet Therapy Cost Effective?
    Sathianathen NJ, Lawrentschuk N, Konety B, Azad AA, Corcoran NM, Bolton DM, Murphy DG.
    Eur Urol Oncol; 2024 Aug 07; 7(4):870-876. PubMed ID: 38057191
    [Abstract] [Full Text] [Related]

  • 4. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
    Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM.
    Urol Oncol; 2019 Oct 07; 37(10):688-695. PubMed ID: 31399302
    [Abstract] [Full Text] [Related]

  • 5. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
    Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A, PEACE-1 investigators.
    Lancet; 2022 Apr 30; 399(10336):1695-1707. PubMed ID: 35405085
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of androgen suppression therapies in advanced prostate cancer.
    Bayoumi AM, Brown AD, Garber AM.
    J Natl Cancer Inst; 2000 Nov 01; 92(21):1731-9. PubMed ID: 11058616
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T, Guetz GD, Chouahnia K, Fossey-Diaz V, Taleb C, Culine S.
    Clin Genitourin Cancer; 2019 Aug 01; 17(4):e806-e813. PubMed ID: 31227430
    [Abstract] [Full Text] [Related]

  • 9. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis.
    Rydzewska LHM, Burdett S, Vale CL, Clarke NW, Fizazi K, Kheoh T, Mason MD, Miladinovic B, James ND, Parmar MKB, Spears MR, Sweeney CJ, Sydes MR, Tran N, Tierney JF, STOPCaP Abiraterone Collaborators.
    Eur J Cancer; 2017 Oct 01; 84():88-101. PubMed ID: 28800492
    [Abstract] [Full Text] [Related]

  • 10. A Cost-effectiveness Analysis of Systemic Therapy for Metastatic Hormone-sensitive Prostate Cancer.
    Sathianathen NJ, Alarid-Escudero F, Kuntz KM, Lawrentschuk N, Bolton DM, Murphy DG, Kim SP, Konety BR.
    Eur Urol Oncol; 2019 Nov 01; 2(6):649-655. PubMed ID: 31411985
    [Abstract] [Full Text] [Related]

  • 11. Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
    Zheng HR, Wen F, Wu YF, Wheeler JRC, Li Q.
    Eur J Cancer Care (Engl); 2017 Nov 01; 26(6):. PubMed ID: 27145493
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Hammerer P, Manka L.
    Urologe A; 2019 Oct 01; 58(10):1185-1197. PubMed ID: 31127324
    [Abstract] [Full Text] [Related]

  • 14. Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone-sensitive prostate cancer.
    Sathianathen NJ, Oestreich MC, Brown SJ, Gupta S, Konety BR, Dahm P, Kunath F.
    Cochrane Database Syst Rev; 2020 Dec 12; 12(12):CD013245. PubMed ID: 33314020
    [Abstract] [Full Text] [Related]

  • 15. Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
    Yoo M, Nelson RE, Haaland B, Dougherty M, Cutshall ZA, Kohli R, Beckstead R, Kohli M.
    J Natl Cancer Inst; 2023 Nov 08; 115(11):1374-1382. PubMed ID: 37436697
    [Abstract] [Full Text] [Related]

  • 16. Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.
    Kinsey EN, Zhang T, Armstrong AJ.
    Cancer J; 2020 Nov 08; 26(1):64-75. PubMed ID: 31977388
    [Abstract] [Full Text] [Related]

  • 17. Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
    Kassem L, Shohdy KS, Abdel-Rahman O.
    Curr Med Res Opin; 2018 May 08; 34(5):903-910. PubMed ID: 29490505
    [Abstract] [Full Text] [Related]

  • 18. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May 08; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 19. Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
    Wang L, Hong H, Alexander GC, Brawley OW, Paller CJ, Ballreich J.
    Value Health; 2022 May 08; 25(5):796-802. PubMed ID: 35500949
    [Abstract] [Full Text] [Related]

  • 20. Addition of docetaxel or abiraterone to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer in Indian population.
    Gupta A, Hussain SM, Sonthwal N, Chaturvedi H.
    J Cancer Res Ther; 2021 May 08; 17(2):389-392. PubMed ID: 34121682
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.